A prospective observational study to investigate real-world IMmunogenicity of theraPeutic Antibodies and to identify faCTors responsible for the interindividual variability
Not Applicable
Recruiting
- Conditions
- IBD, Psoriasis, Palmoplantar pustulosis, Malignant tumors (Melanoma etc.), RA, Autoimmune diseasesD015212 , D011565, D008545, D001172, D001327, D009369
- Registration Number
- JPRN-jRCT1011220023
- Lead Sponsor
- Fukudo Masahide
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Subjects whose medical care and prognostic information can be obtained from medical records
Exclusion Criteria
Subjects presenting with any of the following will be excluded from the study:
1. Subjects who requested non-participation in this study based on a published opt-out document.
2. Subjects who are participating in or interested in participating in other clinical trials during the study period.
3. Subjects who are judged as not suitable for participating in this study by treating physician.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms drive immunogenicity variability in therapeutic antibodies for IBD and psoriasis in the IMPACT study?
How does the immunogenicity of therapeutic antibodies in the IMPACT study compare to standard-of-care biologics for autoimmune diseases?
Which biomarkers are associated with antibody response prediction in palmoplantar pustulosis and melanoma patients within the IMPACT observational trial?
What adverse events are reported with therapeutic antibody use in IBD and RA in the IMPACT study and how are they managed?
Are there combination therapies or competitor drugs showing improved immunogenicity profiles for therapeutic antibodies in autoimmune diseases compared to the IMPACT study?